WO2017046774A3 - Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis - Google Patents

Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis Download PDF

Info

Publication number
WO2017046774A3
WO2017046774A3 PCT/IB2016/055557 IB2016055557W WO2017046774A3 WO 2017046774 A3 WO2017046774 A3 WO 2017046774A3 IB 2016055557 W IB2016055557 W IB 2016055557W WO 2017046774 A3 WO2017046774 A3 WO 2017046774A3
Authority
WO
WIPO (PCT)
Prior art keywords
arteritis
treatment
takayasu
prophylaxis
giant cell
Prior art date
Application number
PCT/IB2016/055557
Other languages
French (fr)
Other versions
WO2017046774A2 (en
Inventor
Kenneth Flanagan
Original Assignee
Prothena Biosciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Limited filed Critical Prothena Biosciences Limited
Publication of WO2017046774A2 publication Critical patent/WO2017046774A2/en
Publication of WO2017046774A3 publication Critical patent/WO2017046774A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides anti-MCAM antibodies that inhibit the ability of human MCAM to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (PMR) or Takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.
PCT/IB2016/055557 2015-09-16 2016-09-16 Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis WO2017046774A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562219611P 2015-09-16 2015-09-16
US62/219,611 2015-09-16

Publications (2)

Publication Number Publication Date
WO2017046774A2 WO2017046774A2 (en) 2017-03-23
WO2017046774A3 true WO2017046774A3 (en) 2017-05-04

Family

ID=56990687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/055557 WO2017046774A2 (en) 2015-09-16 2016-09-16 Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis

Country Status (1)

Country Link
WO (1) WO2017046774A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI660972B (en) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 Anti-mcam antibodies and associated methods of use
JP6728053B2 (en) 2014-03-12 2020-07-22 プロセナ バイオサイエンシーズ リミテッド Anti-mcam antibody and related methods of use
EP3116907A1 (en) 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
CN108129567B (en) * 2018-01-09 2019-02-26 南京任诺药业有限公司 A kind of Humanized anti-human CD146 monoclonal antibody having efficient neutralization activity
AR126001A1 (en) * 2021-06-01 2023-08-30 Symphogen As ANTI-NKG2A ANTIBODIES AND COMPOSITIONS
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170071A1 (en) * 2011-06-06 2012-12-13 Elan Pharmaceuticas, Inc Mcam antagonists and methods of treatment
WO2014039975A2 (en) * 2012-09-10 2014-03-13 Neotope Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2015136469A1 (en) * 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (en) 1982-01-22 1985-10-31 Sandoz Ag METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (en) 1992-12-04 2001-03-15 Medical Res Council MULTIVALENT AND MULTI-SPECIFIC BINDING PROTEINS, THEIR PRODUCTION AND USE
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (en) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Strong homologous promoter from hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
JP5087758B2 (en) 1997-03-10 2012-12-05 オタワ ホスピタル リサーチ インスティチュート Use of nucleic acids containing unmethylated CpG dinucleotides as adjuvants
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ATE385007T1 (en) 1999-02-05 2008-02-15 Samsung Electronics Co Ltd METHOD FOR RECOVERING IMAGE TEXTURES AND DEVICE THEREFOR
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
JP2005516965A (en) 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド Method using anti-MUC18 antibody
CA2472154A1 (en) 2001-12-28 2003-07-17 Abgenix, Inc. Use of antibodies against the muc18 antigen
CA2471849A1 (en) 2001-12-28 2003-07-17 Abgenix, Inc. Antibodies against the muc18 antigen
KR101149777B1 (en) 2002-11-29 2012-06-11 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 Novel neomycin phosphotransferase genes and method for the selection of high-producing recombinant cells
DE10338531A1 (en) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for recloning production cells
WO2006051065A2 (en) 2004-11-10 2006-05-18 Boehringer Ingelheim Pharma Gmbh & Co.Kg Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
ES2523915T5 (en) 2006-12-01 2022-05-26 Seagen Inc Variant Target Binding Agents and Uses Thereof
EP2126093B1 (en) 2007-03-02 2012-10-10 Boehringer Ingelheim Pharma GmbH & Co. KG Improvement of protein production
EP2031064A1 (en) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Method for increasing protein titres

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170071A1 (en) * 2011-06-06 2012-12-13 Elan Pharmaceuticas, Inc Mcam antagonists and methods of treatment
WO2014039975A2 (en) * 2012-09-10 2014-03-13 Neotope Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2015136469A1 (en) * 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALEXANDER JARASCH ET AL: "Developability Assessment During the Selection of Novel Therapeutic Antibodies", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 104, no. 6, 1 June 2015 (2015-06-01), pages 1885 - 1898, XP055217440, ISSN: 0022-3549, DOI: 10.1002/jps.24430 *
LORICERA JAVIER ET AL: "Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients", SEMINARS IN ARTHRITIS AND RHEUMATISM, vol. 44, no. 6, 27 December 2014 (2014-12-27), pages 717 - 723, XP029229325, ISSN: 0049-0172, DOI: 10.1016/J.SEMARTHRIT.2014.12.005 *
NOBBMANN ULF ET AL: "Dynamic light scattering as a relative tool for assessing the molecular integrity and stability of monoclonal antibodies.", BIOTECHNOLOGY & GENETIC ENGINEERING REVIEWS 2007, vol. 24, 2007, pages 117 - 128, XP002764345, ISSN: 0264-8725 *
YING ZHANG ET AL: "Generation and Characterization of a Panel of Monoclonal Antibodies Against Distinct Epitopes of Human CD146", HYBRIDOMA, vol. 27, no. 5, 1 October 2008 (2008-10-01), pages 345 - 352, XP055155690, ISSN: 1554-0014, DOI: 10.1089/hyb.2008.0034 *
ZHENG C ET AL: "Endothelial CD146 is required for in vitro tumor-induced angiogenesis: The role of a disulfide bond in signaling and dimerization", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, PERGAMON, GB, vol. 41, no. 11, 1 November 2009 (2009-11-01), pages 2163 - 2172, XP026644025, ISSN: 1357-2725, [retrieved on 20090405], DOI: 10.1016/J.BIOCEL.2009.03.014 *

Also Published As

Publication number Publication date
WO2017046774A2 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
WO2017046774A3 (en) Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046776A3 (en) Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
PH12016501760A1 (en) Anti-mcam antibodies and associated methods of use
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
WO2018190719A3 (en) Anti-sirp alpha antibodies
MY186414A (en) Human immunodeficiency virus neutralizing antibodies
MX2022004072A (en) Factor xi antibodies and methods of use.
WO2017030823A3 (en) Anti-tigit antibodies
PH12017500803A1 (en) Anti-pd-1 antibodies
WO2017062619A3 (en) Combination therapy for the treatment of cancer
MY188879A (en) Glycan therapeutics and related methods thereof
WO2015157629A3 (en) Antibodies, pharmaceutical compositions and uses thereof
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
MX2019007347A (en) Anti-cd3 antibody, and molecule containing said antibody.
WO2014180889A8 (en) Methods and compositions for the treatment of cancer
WO2019142149A3 (en) Methods of treating cancers with antagonistic anti-pd-1 antibodies
WO2017049038A3 (en) Anti-cd115 antibodies
WO2017117070A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
MX2017006437A (en) Spiro-isoquinoline-1,4'-piperidine compounds having multimodal activity against pain.
MX2021005085A (en) Antibody formulation.
WO2017136731A8 (en) Rapaglutins, novel inhibitors of glut and use thereof
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use
WO2018087143A3 (en) Anti-pd-1 antibodies
WO2017044866A3 (en) Enhanced delivery of drugs to the brain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16770569

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16770569

Country of ref document: EP

Kind code of ref document: A2